Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cenix BioScience Signs Multi-Project Research Agreement with AstraZeneca

Published: Tuesday, June 16, 2009
Last Updated: Tuesday, June 16, 2009
Bookmark and Share
The agreement expands relationship beyond its initial oncology focus, to now include respiratory and inflammation-related indications.

Cenix BioScience GmbH announced that they have signed a new multi-project research agreement with AstraZeneca, thereby expanding their relationship beyond its initial oncology focus, to now include respiratory and inflammation-related indications.

The new agreement calls for Cenix to complete at least three major projects applying the same platform for RNAi-based research.

The work will integrate multi-pass genome-scale screens for the discovery of novel therapeutic target candidates with detailed validation analyses, all using a number of primary human cell types.

Cenix will adapt assays initially developed by AstraZeneca scientists, combining several complementary technology platforms including automated microscopy with Cellenger-based image analysis, to optimize their implementation as high throughput RNAi studies in 384-well and/or 1,536-well formats.

“We particularly welcome the approach chosen by AstraZeneca here, of tightly integrating the discovery screens with subsequent validation studies, a strategy that we have been strongly advocating for some years,” said Dr. Christophe Echeverri, CEO/CSO of Cenix.

Dr. Echeverri continued, “We also greatly appreciate and value the continuing trust that is manifested by this expanded relationship, whose full potential we look forward to realizing together in the months and years to come.”

Financial terms were not disclosed.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cenix BioScience Signs Research Service Agreement with Bayer Pharma AG
Company will undertake a target discovery project for an undisclosed disease indication.
Tuesday, May 06, 2014
Cenix signs RNAi research agreement with SYGNIS
Cenix BioScience GmbH, announced it has signed a research agreement with SYGNIS Bioscience GmbH & Co. KG, a pharmaceutical company dedicated to developing innovative therapies for the treatment of disorders of the central nervous system.
Thursday, November 17, 2011
Cenix BioScience Expands Relationship with AstraZeneca, Signing Multi-Project Research Agreement
The new agreement calls for Cenix to complete three major projects applying same platform for RNAi-based research.
Friday, June 26, 2009
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!